Literature DB >> 28730129

Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report.

Daniel Russell Richardson1, Brian Ellis1, Inderjit Mehmi2, Monique Leys1.   

Abstract

Entities:  

Year:  2017        PMID： 28730129      PMCID： PMC5514288          DOI： 10.18240/ijo.2017.07.28

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  15 in total

1.  Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma.

Authors:  Dimosthenis Mantopoulos; Kari L Kendra; Alan D Letson; Colleen M Cebulla
Journal:  JAMA Ophthalmol       Date:  2015-08       Impact factor: 7.389

Review 2.  Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.

Authors:  Meagan S Barbee; Adebayo Ogunniyi; Troy Z Horvat; Thu-Oanh Dang
Journal:  Ann Pharmacother       Date:  2015-05-19       Impact factor: 3.154

3.  Bilateral Anterior Uveitis Associated with Nivolumab Therapy.

Authors:  Justin Karlin; Ryan Gentzler; Jeffrey Golen
Journal:  Ocul Immunol Inflamm       Date:  2016-09-06       Impact factor: 3.070

4.  A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.

Authors:  Khawla Abu Samra; Manuel Valdes-Navarro; Stacey Lee; Robert Swan; C Stephen Foster; Stephen D Anesi
Journal:  Eur J Ophthalmol       Date:  2016-04-12       Impact factor: 2.597

5.  Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.

Authors:  Elena Gianchecchi; Domenico Vittorio Delfino; Alessandra Fierabracci
Journal:  Autoimmun Rev       Date:  2013-06-20       Impact factor: 9.754

6.  Ipilimumab-Associated Retinopathy.

Authors:  Jonathan Crews; Aniruddha Agarwal; Loren Jack; Ding Xu; Diana V Do; Quan Dong Nguyen
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-06       Impact factor: 1.300

7.  CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.

Authors:  Qianli Meng; Peizeng Yang; Bing Li; Hongyan Zhou; Xiangkun Huang; Lianxiang Zhu; Yalin Ren; Aize Kijlstra
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-10       Impact factor: 4.799

Review 8.  Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review.

Authors:  F C Fierz; F Meier; K Chaloupka; C Böni
Journal:  Klin Monbl Augenheilkd       Date:  2016-04-26       Impact factor: 0.700

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma.

Authors:  Laura Hahn; Kathryn L Pepple
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-05-10
View more
  9 in total

1.  Diagnosis and Management of Rare Immune-Related Adverse Events.

Authors:  Sara R Schoenfeld; Mary E Aronow; Rebecca Karp Leaf; Michael Dougan; Kerry L Reynolds
Journal:  Oncologist       Date:  2019-11-06

2.  Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.

Authors:  Michel M Sun; Ralph D Levinson; Artur Filipowicz; Stephen Anesi; Henry J Kaplan; Wei Wang; Debra A Goldstein; Sapna Gangaputra; Robert T Swan; H Nida Sen; Lynn K Gordon
Journal:  Ocul Immunol Inflamm       Date:  2019-03-01       Impact factor: 3.070

Review 3.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 4.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

5.  Corneal ulceration associated with Nivolumab use.

Authors:  Jack S Parker; Wyatt Feagin; Christopher Wang; Marius Heersink; John S Parker
Journal:  Am J Ophthalmol Case Rep       Date:  2019-02-07

6.  Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer.

Authors:  Christopher R Dermarkarian; Nimesh A Patel; Victor M Villegas; J William Harbour
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-07

7.  Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Authors:  Florence Chaudot; Pascal Sève; Antoine Rousseau; Alexandre Thibault Jacques Maria; Pierre Fournie; Pierre Lozach; Jeremy Keraen; Marion Servant; Romain Muller; Baptiste Gramont; Sara Touhami; Habeeb Mahmoud; Pierre-Antoine Quintart; Stéphane Dalle; Olivier Lambotte; Laurent Kodjikian; Yvan Jamilloux
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

8.  Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report.

Authors:  Reina Miyamoto; Hiroyuki Nakashizuka; Koji Tanaka; Yu Wakatsuki; Hajime Onoe; Ryusaburo Mori; Akiyuki Kawamura
Journal:  BMC Ophthalmol       Date:  2020-06-08       Impact factor: 2.209

9.  Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis).

Authors:  Julia Canestraro; Anna Do; Seth D Potash; Joseph Panarelli; Meghan Berkenstock; David H Abramson; Jasmine H Francis
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.